# Nuclear Medicine & Radiopharmaceuticals Investment Thesis
> Explore the growth of theranostics and nuclear medicine. Strategic deeper-dive into market structure, radiopharmaceutical supply chains, and clinical ROI.

Tags: nuclear-medicine, radiopharmaceuticals, theranostics, healthcare-investment, oncology, market-analysis, precision-medicine, biotech
## Nuclear Medicine Strategic Overview
* **Global Market Scaling**: ~$17B global market in 2024 with a ~15% CAGR.
* **Technological Shift**: Evolution from diagnostic tools (PET-CT/SPECT) to theranostic platforms that both locate and destroy cancer cells.

## Technical Foundations & Radiopharmaceuticals
* **Function vs. Anatomy**: Unlike CT/MRI, nuclear medicine focuses on cellular behavior and metabolism.
* **Key Isotopes**: Includes FDG (F-18) for oncology, Ga-68 for neuroendocrine tumors, and Lu-177 for therapeutics (e.g., Pluvicto).
* **Logistical Moats**: Short isotope half-lives (e.g., F-18 at 110 min) create high barriers to entry for production and distribution.

## The Theranostics Revolution
* **Precision Oncology**: Theranostics pairs diagnostic imaging (Ga-68) with molecular therapy (Lu-177) to target receptors like PSMA in prostate cancer.
* **Clinical Outcomes**: VISION trial data shows Lu-177 PSMA provides an 8.7-month gain in radiographic progression-free survival (PFS).
* **Economic Value**: High value per outcome due to targeted delivery and reduced systemic toxicity compared to chemotherapy.

## Market Structure & Brazil Case Study
* **Value Chain**: Spans from isotope production (Cyclotrons) to radiopharmaceutical manufacturing and clinical service delivery.
* **Brazil Infrastructure**: Only 111 PET scanners for 215 million people, with 0.52 scanners per million pop (10x lower than the USA).
* **Investment Thesis**: Opportunities in vertical integration, regional expansion into underserved markets, and M&A of independent clinics.

## Industrial Production Barriers
* **Capital Intensity**: Minimum capex for a cyclotron facility is ~$7-12M USD.
* **Regulatory Complexity**: Requires specialized licensing from bodies like ANVISA and CNEN.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.